Z. Yapici Et Al. , "Long-Term Safety, Rollover Study of Adjunctive Everolimus in Patients with Tuberous Sclerosis Complex (TSC)-Associated Treatment-Refractory Seizures Who Continue to Benefit from Everolimus Treatment after Completion of EXIST-3," 13th European Congress on Epileptology , vol.59, Vienna, Austria, 2018
Yapici, Z. Et Al. 2018. Long-Term Safety, Rollover Study of Adjunctive Everolimus in Patients with Tuberous Sclerosis Complex (TSC)-Associated Treatment-Refractory Seizures Who Continue to Benefit from Everolimus Treatment after Completion of EXIST-3. 13th European Congress on Epileptology , (Vienna, Austria).
Yapici, Z., Fan, P. -., Lawson, J. A., Belousova, E., Gazri, H. E., Ridolfi, A., ... Herbst, F.(2018). Long-Term Safety, Rollover Study of Adjunctive Everolimus in Patients with Tuberous Sclerosis Complex (TSC)-Associated Treatment-Refractory Seizures Who Continue to Benefit from Everolimus Treatment after Completion of EXIST-3 . 13th European Congress on Epileptology, Vienna, Austria
Yapici, Cengiz Et Al. "Long-Term Safety, Rollover Study of Adjunctive Everolimus in Patients with Tuberous Sclerosis Complex (TSC)-Associated Treatment-Refractory Seizures Who Continue to Benefit from Everolimus Treatment after Completion of EXIST-3," 13th European Congress on Epileptology, Vienna, Austria, 2018
Yapici, Cengiz Et Al. "Long-Term Safety, Rollover Study of Adjunctive Everolimus in Patients with Tuberous Sclerosis Complex (TSC)-Associated Treatment-Refractory Seizures Who Continue to Benefit from Everolimus Treatment after Completion of EXIST-3." 13th European Congress on Epileptology , Vienna, Austria, 2018
Yapici, Z. Et Al. (2018) . "Long-Term Safety, Rollover Study of Adjunctive Everolimus in Patients with Tuberous Sclerosis Complex (TSC)-Associated Treatment-Refractory Seizures Who Continue to Benefit from Everolimus Treatment after Completion of EXIST-3." 13th European Congress on Epileptology , Vienna, Austria.
@conferencepaper{conferencepaper, author={Cengiz YALÇINKAYA Et Al. }, title={Long-Term Safety, Rollover Study of Adjunctive Everolimus in Patients with Tuberous Sclerosis Complex (TSC)-Associated Treatment-Refractory Seizures Who Continue to Benefit from Everolimus Treatment after Completion of EXIST-3}, congress name={13th European Congress on Epileptology}, city={Vienna}, country={Austria}, year={2018}}